AR095070A1 - Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica - Google Patents

Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica

Info

Publication number
AR095070A1
AR095070A1 ARP140100771A ARP140100771A AR095070A1 AR 095070 A1 AR095070 A1 AR 095070A1 AR P140100771 A ARP140100771 A AR P140100771A AR P140100771 A ARP140100771 A AR P140100771A AR 095070 A1 AR095070 A1 AR 095070A1
Authority
AR
Argentina
Prior art keywords
cefimadin
pharmaceutical composition
antibiotic
steroid
blepharitis
Prior art date
Application number
ARP140100771A
Other languages
English (en)
Inventor
Attar Mayssa
A Bhat Smita
E Garst Michael
D Swift Brandon
Chow Ken
C Sinha Santosh
Wang Liming
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR095070A1 publication Critical patent/AR095070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto híbrido que comprende una porción antibiótica y una porción esteroide, o una sal farmacéutica de la misma, que se conectan vía dos enlaces covalentes separados con un enlazador de manera que dichos enlaces covalentes se degradan en vivo para producir los respectivos antibiótico y esteroide independientemente. La porción. antibiótica, es seleccionada entre el grupo formado por levofloxacina, moxifloxacina, gatifloxacina, clindamicina, besifloxacina, gemifloxacina, trovafloxacina, ofloxacina, ciprofloxacina, esparfloxacina, grepafloxacina, norfoxacina, enoxacina, lomefloxacina, fleroxacina, tosufloxacina, prulifloxacina, pazufloxacina, clinafloxacina, garenoxacina, sitafloxacina, loracarbef, cefalexina, cefuroxima, ceftriaxona, ceftaxima, ceftizoxima, ceftibuten, ceftazidima, cefprozil, cefpodoxima, cefoxitina, cefotetan, cefotaxima, cefoperazona, cefixima, cefepima, cefditoren, cefdinir, cefoperaxona, moxalactam, cefazolina, cefamandol, cefadroxil, cefaclor, cefalotina, cefradina, cefacetril, cefalotina, cloramfenicol, tobramicina, estreptomicina, gentamicina, canamicina, amicacina, netilmicina, penicilina g, ticarcilina, meticilina, fenticilina, cloxacilina, dicloxacilina, nafcilina, oxacilina, eritromicina y azitromicina. La porción esteroide es seleccionada entre dexmetasona, betametasona, acetónido de triamcinolona, prednisolona e hidrocortisona. Uso del compuesto hibrido, en donde cada enlace es un enlace éster o un enlace amida, para preparar una composición farmacéutica de utilidad para administrar a un ojo de un mamífero con una infección bacteriana o una inflamación que afecta dicho ojo. La infección bacteriana es seleccionada entre: conjuntivitis, queratitis, blefaritis, endoftalmitis, dacirocistitis, hordéolo, úlceras cornéales, blefaritis anterior, blefaritis posterior, disfunción de glándula meibomiana, enfermedad de ojo seco, (queratoconjuntivitis sicca) dolor ocular e inflamación post-cirugía ocular, conjuntivitis bacteriana, uveítis anterior, ojo rojo, hiperemia, inflamación post- quirúrgica, condiciones inflamatorias de conjuntiva palpebral y bulbar, cornea, y segmento anterior del globo, tal como conjuntivitis alérgica, rosácea ocular, ojo seco blefaritis, endoftalmitis, disfunción. de glándula.meibomiana, queratitis punteada. superficial, queratitis de herpes zoster, iritis, ciclitis, conjuntivitis infectiva seleccionada, daño corneal por radiación química, o quemadura térmica, penetración de cuerpos extraños, y alergia. Composición farmacéutica que comprende al compuesto hibrido, y en donde dicha composición está formulada para administración oftálmica tópica.
ARP140100771A 2013-03-08 2014-03-07 Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica AR095070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361775121P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
AR095070A1 true AR095070A1 (es) 2015-09-16

Family

ID=50382688

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100771A AR095070A1 (es) 2013-03-08 2014-03-07 Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica

Country Status (16)

Country Link
US (1) US20140256660A1 (es)
EP (1) EP2964267A1 (es)
JP (1) JP2016510753A (es)
KR (1) KR20150128856A (es)
CN (1) CN105025930A (es)
AR (1) AR095070A1 (es)
AU (1) AU2014225682A1 (es)
BR (1) BR112015021834A2 (es)
CA (1) CA2903438A1 (es)
IL (1) IL241076A0 (es)
MX (1) MX2015011847A (es)
RU (1) RU2015138893A (es)
SG (1) SG11201507250YA (es)
TW (1) TW201444559A (es)
WO (1) WO2014138375A1 (es)
ZA (1) ZA201506495B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138403A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Antibiotic conjugates
MX2015011948A (es) 2013-03-08 2015-12-09 Allergan Inc Antibioticos conjugados directamente relacionados con farmacos esteroides.
US10272158B2 (en) 2014-07-03 2019-04-30 Board Of Regents, The University Of Texas System Compounds for treating biofilm infection
CN105001296B (zh) * 2015-07-14 2016-11-30 中国人民解放军第三军医大学 一种一氧化氮供体型地塞米松及制备方法与用途
EP3394080B1 (en) 2015-12-23 2023-06-07 The University Of British Columbia Lipid-linked prodrugs
SG11202109152UA (en) * 2019-06-03 2021-12-30 Aihol Corp Hyaluronan conjugates and uses thereof
WO2022232602A1 (en) * 2021-04-29 2022-11-03 Aerie Pharmaceuticals, Inc. Stable isoquinoline-corticosteroid conjugates and uses thereof
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
HRP20030324A2 (en) * 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
EP1633403A2 (en) * 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Codrugs of diclofenac
US20080138350A1 (en) * 2006-10-20 2008-06-12 Bennett Michael D Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
US20090162858A1 (en) * 2007-09-18 2009-06-25 Cornish Virginia W Orthogonal chemical inducer of dimerization
MX2008014515A (es) * 2008-09-09 2010-04-29 Allergan Inc Suspension oftalmica para uso ocular.

Also Published As

Publication number Publication date
TW201444559A (zh) 2014-12-01
RU2015138893A (ru) 2017-04-13
US20140256660A1 (en) 2014-09-11
BR112015021834A2 (pt) 2017-07-18
CN105025930A (zh) 2015-11-04
CA2903438A1 (en) 2014-09-12
AU2014225682A1 (en) 2015-09-24
ZA201506495B (en) 2017-08-30
JP2016510753A (ja) 2016-04-11
EP2964267A1 (en) 2016-01-13
WO2014138375A1 (en) 2014-09-12
MX2015011847A (es) 2016-01-08
KR20150128856A (ko) 2015-11-18
SG11201507250YA (en) 2015-10-29
IL241076A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AR095070A1 (es) Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición farmacéutica
DOP2022000278A (es) Inhibidores de cisteína proteasas y sus métodos de uso
AR095073A1 (es) Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición
WO2020150417A2 (en) Compounds and compositions for treating conditions associated with sting activity
EP3817820A1 (en) Compounds and compositions for treating conditions associated with sting activity
PE20181016A1 (es) Compuestos antivirales de fosfodiamida de ester de beta aminoacido
AR054186A1 (es) Derivados de tetrahidroindazolona y tetrahidroindolona
JP2014527407A5 (es)
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
WO2021067801A1 (en) Compounds and compositions for treating conditions associated with sting activity
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
AR087471A1 (es) Metodos de tratamiento de enfermedades degenerativas de la retina
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
WO2021067805A1 (en) Oxalamide heterobycyclic compounds and compositions for treating conditions associated with sting activity
RU2014123471A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ПРОИЗВОДНЫХ 4-ПРЕГЕНЕН-11β-17-21-ТРИОЛ-3,20-ДИОНА
MXPA06002088A (es) Analogos de rifamicina y usos de los mismos.
JP2007516291A (ja) リファマイシンアナログおよびその使用法
JP2014533275A5 (es)
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
EA201892153A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
AR095071A1 (es) Compuesto híbrido con una porción antibiótica y una porción esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica oftálmica y dicha composición
EP4182030A1 (en) Compounds and compositions for treating conditions associated with sting activity
EA201992343A1 (ru) Замещенные бициклические гетероциклические соединения в качестве ингибиторов надфн-оксидазы
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300

Legal Events

Date Code Title Description
FB Suspension of granting procedure